These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 15164709

  • 1. [Induction chemotherapy using vinorelbine, cisplatin, and UFT in advanced pharyngeo-laryngeal carcinomas: results of a phase II study].
    Rubio Suárez A, Teigeiro Núñez V, Gallo Terán J, Señaris González B, Mesuro Domínguez N.
    Acta Otorrinolaringol Esp; 2003 Dec; 54(10):697-703. PubMed ID: 15164709
    [Abstract] [Full Text] [Related]

  • 2. Long-term results of a phase II trial of induction chemotherapy with uracil-ftegafur (UFT), vinorelbine, and cisplatin (UFTVP) followed by radiotherapy concomitant with UFT and carboplatin (RT/UFTJ) in a primary site preservation setting for resectable locally advanced squamous cell carcinoma of larynx and hypopharynx.
    Rivera F, Vega-Villegas ME, López-Brea MF, García-Castaño A, de Juan A, Collado A, Galdós P, Rubio A, del Valle A, Rama J, Sanz-Ortiz J.
    Laryngoscope; 2004 Jul; 114(7):1163-9. PubMed ID: 15235341
    [Abstract] [Full Text] [Related]

  • 3. Laryngeal preservation by induction chemotherapy plus radiotherapy in locally advanced head and neck cancer: the M. D. Anderson Cancer Center experience.
    Shirinian MH, Weber RS, Lippman SM, Dimery IW, Earley CL, Garden AS, Michaelson J, Morrison WH, Kramer A, Byers R.
    Head Neck; 1994 Jul; 16(1):39-44. PubMed ID: 7510276
    [Abstract] [Full Text] [Related]

  • 4. Long term results of a phase II trial of induction chemotherapy with uracil-ftegafur (UFT), vinorelbine and cisplatin (UFTVP) followed by radiotherapy concomitant with UFT and carboplatin (RT/UFTJ) in non-resectable locally advanced (stage IV-B) squamous cell head and neck carcinoma and peripheral blood stem cell support (PBSCS) with febrile neutropenia.
    Rivera F, Vega-Villegas ME, López-Brea MF, García-Castaño A, de Juan A, Ramos FJ, Collado A, Galdós P, Rubio A, del Valle A, Rama J, Mayorga M, Sanz-Ortiz J.
    Clin Transl Oncol; 2007 Jan; 9(1):40-7. PubMed ID: 17272229
    [Abstract] [Full Text] [Related]

  • 5. Randomized phase II study of cisplatin and 5-FU continuous infusion (PF) versus cisplatin, UFT and vinorelbine (UFTVP) as induction chemotherapy in locally advanced squamous cell head and neck cancer (LA-SCHNC).
    Rivera F, Vega-Villegas ME, López-Brea M, Isla D, Mayorga M, Galdós P, Rubio A, Del Valle A, García-Reija F, García-Montesinos B, Rodríguez-Iglesias J, Mayordomo J, Rama J, Saiz-Bustillo R, Sanz-Ortiz J.
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):253-61. PubMed ID: 17901953
    [Abstract] [Full Text] [Related]

  • 6. Conservative surgery in T3-T4 pharyngolaryngeal squamous cell carcinoma: an alternative to radiation therapy and to total laryngectomy for good responders to induction chemotherapy.
    Lecanu JB, Monceaux G, Périé S, Angelard B, St Guily JL.
    Laryngoscope; 2000 Mar; 110(3 Pt 1):412-6. PubMed ID: 10718429
    [Abstract] [Full Text] [Related]

  • 7. Prospective assessment of patterns of failure after high-precision definitive (chemo)radiation in head-and-neck squamous cell carcinoma.
    Gupta T, Jain S, Agarwal JP, Ghosh-Laskar S, Phurailatpam R, Pai-Shetty R, Dinshaw KA.
    Int J Radiat Oncol Biol Phys; 2011 Jun 01; 80(2):522-31. PubMed ID: 20646862
    [Abstract] [Full Text] [Related]

  • 8. Searching for less toxic larynx preservation: a need for common definitions and metrics.
    Forastiere AA, Trotti AM.
    J Natl Cancer Inst; 2009 Feb 04; 101(3):129-31. PubMed ID: 19176460
    [No Abstract] [Full Text] [Related]

  • 9. Concurrent chemoradiotherapy for T4 patients with hypopharyngeal and laryngeal squamous cell carcinomas.
    Nishimura G, Tsukuda M, Horiuchi C, Satake K, Yoshida T, Nagao J, Kawakami M, Kondo N, Arai Y, Taguchi T, Matsuda H, Mikami Y.
    Auris Nasus Larynx; 2007 Dec 04; 34(4):499-504. PubMed ID: 17604583
    [Abstract] [Full Text] [Related]

  • 10. Feasibility, toxicity, and efficacy of short induction chemotherapy of docetaxel plus cisplatin or carboplatin (TP) followed by concurrent chemoradio-therapy for organ preservation in advanced cancer of the hypopharynx, larynx, and base of tongue. Early results.
    Semrau S, Waldfahrer F, Lell M, Linke R, Klautke G, Kuwert T, Uder M, Iro H, Fietkau R.
    Strahlenther Onkol; 2011 Jan 04; 187(1):15-22. PubMed ID: 21234526
    [Abstract] [Full Text] [Related]

  • 11. [Induction chemotherapy and larynx preservation: is such practice useful?].
    Sarini J, Bocciolini C, Fournier C, Penel N, Kara A, Van JT, Lefebvre JL.
    Bull Cancer; 2002 Apr 04; 89(4):411-7. PubMed ID: 12016041
    [Abstract] [Full Text] [Related]

  • 12. Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation.
    Posner MR, Norris CM, Wirth LJ, Shin DM, Cullen KJ, Winquist EW, Blajman CR, Mickiewicz EA, Frenette GP, Plinar LF, Cohen RB, Steinbrenner LM, Freue JM, Gorbunova VA, Tjulandin SA, Raez LE, Adkins DR, Tishler RB, Roessner MR, Haddad RI, TAX 324 Study Group.
    Ann Oncol; 2009 May 04; 20(5):921-7. PubMed ID: 19179556
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, ± Docetaxel for Larynx Preservation.
    Janoray G, Pointreau Y, Garaud P, Chapet S, Alfonsi M, Sire C, Jadaud E, Calais G.
    J Natl Cancer Inst; 2016 Apr 04; 108(4):. PubMed ID: 26681800
    [Abstract] [Full Text] [Related]

  • 15. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group.
    Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T.
    J Natl Cancer Inst; 1996 Jul 03; 88(13):890-9. PubMed ID: 8656441
    [Abstract] [Full Text] [Related]

  • 16. Phase II trial of cisplatin, tegafur plus uracil and leucovorin as neoadjuvant chemotherapy in patients with squamous cell carcinoma of the oropharynx and hypopharynx.
    Wang HM, Hsueh CT, Wang CS, Chen IH, Liao CT, Tsai MH, Yeh SP, Chang JT.
    Anticancer Drugs; 2005 Apr 03; 16(4):447-53. PubMed ID: 15746582
    [Abstract] [Full Text] [Related]

  • 17. Laryngeal preservation for advanced laryngeal and hypopharyngeal cancers.
    Clayman GL, Weber RS, Guillamondegui O, Byers RM, Wolf PF, Frankenthaler RA, Morrison WH, Garden AS, Hong WK, Goepfert H.
    Arch Otolaryngol Head Neck Surg; 1995 Feb 03; 121(2):219-23. PubMed ID: 7840931
    [Abstract] [Full Text] [Related]

  • 18. Phase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck.
    Herchenhorn D, Dias FL, Viegas CM, Federico MH, Araújo CM, Small I, Bezerra M, Fontão K, Knust RE, Ferreira CG, Martins RG.
    Int J Radiat Oncol Biol Phys; 2010 Nov 01; 78(3):696-702. PubMed ID: 20421154
    [Abstract] [Full Text] [Related]

  • 19. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation.
    Pointreau Y, Garaud P, Chapet S, Sire C, Tuchais C, Tortochaux J, Faivre S, Guerrif S, Alfonsi M, Calais G.
    J Natl Cancer Inst; 2009 Apr 01; 101(7):498-506. PubMed ID: 19318632
    [Abstract] [Full Text] [Related]

  • 20. Larynx preservation with combined chemotherapy and radiation therapy in advanced but resectable head and neck cancer.
    Pfister DG, Strong E, Harrison L, Haines IE, Pfister DA, Sessions R, Spiro R, Shah J, Gerold F, McLure T.
    J Clin Oncol; 1991 May 01; 9(5):850-9. PubMed ID: 2016629
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.